TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis



Status:Recruiting
Conditions:Psoriasis, Dermatology, Dermatology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:12 - Any
Updated:12/9/2018
Start Date:November 28, 2018
End Date:September 2020
Contact:Incyte Corporation Call Center (US)
Email:medinfo@incyte.com
Phone:1.855.463.3463

Use our guide to learn which trials are right for you!

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of ruxolitinib cream in
adolescents and adults with atopic dermatitis (AD).


Inclusion Criteria:

- Adolescents aged ≥ 12 to 17 years, inclusive, and men and women aged ≥ 18 years.

- Participants diagnosed with AD as defined by the Hanifin and Rajka criteria.

- AD duration of at least 2 years.

- Participants with an IGA score of 2 to 3 at screening and baseline (VC period) and 0
to 4 at Week 8 (long-term safety period).

- Participants with % BSA (excluding scalp) of AD involvement of 3% to 20% at screening
and baseline (VC period) and 0% to 20% at Week 8 (long-term safety period).

- Participants who agree to discontinue all agents used to treat AD from screening
through the final follow-up visit.

- Participants who have at least 1 "target lesion" that measures approximately 10 cm^2
or more at screening and baseline. Lesion must be representative of the participant's
disease state and not be located on the hands, feet, or genitalia.

- Willingness to avoid pregnancy or fathering of children.

Exclusion Criteria:

- Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined
by the investigator in the 4 weeks prior to baseline.

- Concurrent conditions and history of other diseases:

- Immunocompromised.

- Chronic or acute infection requiring treatment with systemic antibiotics,
antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before
baseline.

- Active acute bacterial, fungal, or viral skin infection within 1 week before
baseline.

- Any other concomitant skin disorder, pigmentation, or extensive scarring that, in
the opinion of the investigator, may interfere with the evaluation of AD lesions
or compromise participant safety.

- Presence of AD lesions only on the hands or feet without prior history of
involvement of other classical areas of involvement such as the face or the
folds.

- Other types of eczema.

- Any serious illness or medical, physical, or psychiatric condition(s) that, in the
investigator's opinion, would interfere with full participation in the study,
including administration of study drug and attending required study visits; pose a
significant risk to the participant; or interfere with interpretation of study data.

- Use of any of the following treatments within the indicated washout period before
baseline:

- 5 half-lives or 12 weeks, whichever is longer - biologic agents (eg, dupilumab).

- 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogs,
cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or
immunomodulating agents (eg, mycophenolate or tacrolimus).

- 2 weeks - immunizations and sedating antihistamines, unless on long-term stable
regimen (nonsedating antihistamines are permitted).

- 1 week - use of other topical treatments for AD (other than bland emollients).
Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not
exceed 2 baths per week and their frequency remains the same throughout the
study.

- Participants who have previously received JAK inhibitors, systemic or topical.

- Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV
radiation within 2 weeks prior to baseline and/or intention to have such exposure
during the study, which is thought by the investigator to potentially impact the
participant's AD.

- Positive serology test results at screening for HIV antibody.

- Liver function tests: aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) ≥ 2 × upper limit of normal (ULN); alkaline phosphatase and/or bilirubin > 1.5 ×
ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and
direct bilirubin < 35%).

- Pregnant or lactating participants, or those considering pregnancy.

- History of alcoholism or drug addiction within 1 year before screening or current
alcohol or drug use that, in the opinion of the investigator, will interfere with the
participant's ability to comply with the administration schedule and study
assessments.

- Current treatment or treatment within 30 days or 5 half-lives (whichever is longer)
before baseline with another investigational medication or current enrollment in
another investigational drug protocol.
We found this trial at
21
sites
Norman, Oklahoma 73069
?
mi
from
Norman, OK
Click here to add this to my saved trials
911 Park Avenue
New York, New York 10075
212-710-9855
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Calgary,
Click here to add this to my saved trials
Carrollton, Texas 75010
?
mi
from
Carrollton, TX
Click here to add this to my saved trials
Forest Hills, New York 11375
?
mi
from
Forest Hills, NY
Click here to add this to my saved trials
17271 Brookhurst Street
Fountain Valley, California 92708
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Garden Grove, California 92843
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Gresham, Oregon 97030
?
mi
from
Gresham, OR
Click here to add this to my saved trials
Indianapolis, Indiana 46256
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Miami, Florida 33142
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33147
?
mi
from
Miami, FL
Click here to add this to my saved trials
3810 Springhurst Boulevard
New Albany, Indiana 47150
?
mi
from
New Albany, IN
Click here to add this to my saved trials
Normal, Illinois 61761
?
mi
from
Normal, IL
Click here to add this to my saved trials
Phoenix, Arizona 85018
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
3100 Duraleigh Rd
Raleigh, North Carolina 27612
(919) 781-2514
Wake Research Associates, LLC Wake Research is an Organization of Unified Investigational Sites working closely...
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Rockville, Maryland 20850
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
Rogers, AR
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Upland, California 91786
?
mi
from
Upland, CA
Click here to add this to my saved trials
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials